# Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07189455/  
OnCo record `nct07189455` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing ZG006 in non-small-cell lung cancer, now recruiting.

## Summary

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07189455, led by Suzhou Zelgen Biopharmaceuticals, and recruiting on the registry. Official title: A Multicenter, Randomised, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer. Planned enrolment is 420 participants (estimated). The study started in 2025-12-12 and primary completion is expected in 2028-10. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07189455
- Phase: 3
- Setting: A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
- Sponsor: Suzhou Zelgen Biopharmaceuticals
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT07189455: https://clinicaltrials.gov/study/NCT07189455

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [ZG006](https://onco.cc/drugs/zg006/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct07189455.json